## Protocol Section
### Identification Module
**NCT ID:** NCT05051579

**Brief Title:** A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities

**Official Title:** A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities

#### Organization Study ID Info
**ID:** 18210
#### Organization
**Class:** INDUSTRY
**Full Name:** Eli Lilly and Company
#### Secondary ID Infos
**Domain:** Eli Lilly and Company
**ID:** J2A-MC-GZGI
**Type:** OTHER
**ID:** 2021-002805-88
**Type:** EUDRACT_NUMBER
### Status Module
#### Completion Date
**Date:** 2022-11-22

**Type:** ACTUAL

#### Expanded Access Info
#### Last Update Post Date
**Date:** 2023-09-13

**Type:** ACTUAL

**Last Update Submit Date:** 2023-08-23

**Overall Status:** COMPLETED

#### Primary Completion Date
**Date:** 2022-08-25

**Type:** ACTUAL

#### Results First Post Date
**Date:** 2023-09-13

**Type:** ACTUAL

**Results First Submit Date:** 2023-08-23

**Results First Submit QC Date:** 2023-08-23

#### Start Date
**Date:** 2021-09-29

**Type:** ACTUAL

**Status Verified Date:** 2023-08

#### Study First Post Date
**Date:** 2021-09-21
**Type:** ACTUAL
**Study First Submit Date:** 2021-09-17
**Study First Submit QC Date:** 2021-09-17
### Sponsor Collaborators Module

#### Lead Sponsor

**Class:** INDUSTRY

**Name:** Eli Lilly and Company

#### Responsible Party

**Type:** SPONSOR

### Oversight Module

**Is FDA Regulated Device:** False

**Is FDA Regulated Drug:** True

**Oversight Has DMC:** False

### Description Module

**Brief Summary:** The main purpose of the study was to assess the effect of LY3502970 in participants who have obesity or are overweight.

### Conditions Module

**Conditions:**

- Obesity

- Overweight and Obesity

### Design Module

#### Design Info

**Allocation:** RANDOMIZED

**Intervention Model:** PARALLEL

##### Masking Info

**Masking:** DOUBLE

**Who Masked:**

- PARTICIPANT

- INVESTIGATOR

**Primary Purpose:** TREATMENT

#### Enrollment Info

**Count:** 272

**Type:** ACTUAL

**Phases:**

- PHASE2

**Study Type:** INTERVENTIONAL

### Arms Interventions Module

#### Arm Group 1

**Description:** Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks.

**Intervention Names:**

- Drug: LY3502970

**Label:** 12 milligram (mg) LY3502970

**Type:** EXPERIMENTAL

#### Arm Group 2

**Description:** Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks.

**Intervention Names:**

- Drug: LY3502970

**Label:** 24 mg LY3502970

**Type:** EXPERIMENTAL

#### Arm Group 3

**Description:** Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.

**Intervention Names:**

- Drug: LY3502970

**Label:** 36 mg-1 LY3502970

**Type:** EXPERIMENTAL

#### Arm Group 4

**Description:** Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.

**Intervention Names:**

- Drug: LY3502970

**Label:** 36 mg-2 LY3502970

**Type:** EXPERIMENTAL

#### Arm Group 5

**Description:** Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.

**Intervention Names:**

- Drug: LY3502970

**Label:** 45 mg-1 LY3502970

**Type:** EXPERIMENTAL

#### Arm Group 6

**Description:** Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.

**Intervention Names:**

- Drug: LY3502970

**Label:** 45 mg-2 LY3502970

**Type:** EXPERIMENTAL

#### Arm Group 7

**Description:** Participants received placebo administered orally once daily until 36 weeks.

**Intervention Names:**

- Drug: Placebo

**Label:** Placebo

**Type:** PLACEBO_COMPARATOR

### Interventions

#### Intervention 1

**Arm Group Labels:**

- 12 milligram (mg) LY3502970

- 24 mg LY3502970

- 36 mg-1 LY3502970

- 36 mg-2 LY3502970

- 45 mg-1 LY3502970

- 45 mg-2 LY3502970

**Description:** Administered orally

**Name:** LY3502970

**Type:** DRUG

#### Intervention 2

**Arm Group Labels:**

- Placebo

**Description:** Administered orally

**Name:** Placebo

**Type:** DRUG

### Outcomes Module

#### Primary Outcomes

**Description:** Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.

**Measure:** Percent Change From Baseline in Body Weight in LY3502970 and Placebo

**Time Frame:** Baseline, Week 26

#### Secondary Outcomes

**Description:** LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.

**Measure:** Percent Change From Baseline in Body Weight in LY3502970 and Placebo

**Time Frame:** Baseline, Week 36

**Description:** LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.

**Measure:** Change From Baseline in Body Weight in LY3502970 and Placebo

**Time Frame:** Baseline, Week 26

**Description:** LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.

**Measure:** Change From Baseline in Body Weight in LY3502970 and Placebo

**Time Frame:** Baseline, Week 36

**Description:** LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.

**Measure:** Change From Baseline in Waist Circumference in LY3502970 and Placebo

**Time Frame:** Baseline, Week 26

**Description:** LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.

**Measure:** Change From Baseline in Waist Circumference in LY3502970 and Placebo

**Time Frame:** Baseline, Week 36

**Description:** LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.

**Measure:** Change From Baseline in BMI in LY3502970 and Placebo

**Time Frame:** Baseline, Week 26

**Description:** LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.

**Measure:** Change From Baseline in BMI in LY3502970 and Placebo

**Time Frame:** Baseline, Week 36

**Description:** Percentage of participants with \>=5% body weight loss was reported.

**Measure:** Percentage of Participants With >=5% Body Weight Loss

**Time Frame:** Week 26

**Description:** Percentage of participants with \>=10% body weight loss was reported.

**Measure:** Percentage of Participants With >=10% Body Weight Loss

**Time Frame:** Week 26

**Description:** Percentage of participants with \>=5% body weight loss was reported.

**Measure:** Percentage of Participants With >=5% Body Weight Loss

**Time Frame:** Week 36

**Description:** Percentage of participants with \>=10% body weight loss was reported.

**Measure:** Percentage of Participants With >=10% Body Weight Loss

**Time Frame:** Week 36

### Eligibility Module

**Eligibility Criteria:** Inclusion Criteria:

* Have a body mass index (BMI) of ≥30-kilogram square meter (kg/m²)
* Have a BMI ≥27 kg/m² and \<30 kg/m² with at least 1 of the following weight-related comorbidities eg; \[Have hypertension, or dyslipidemia, cardiovascular disease\]
* Have had a stable body weight for the 3 months prior to randomization (not more than 5% body weight gain and/or loss)

Exclusion Criteria:

* Have any prior diagnosis of diabetes
* Have a prior or planned surgical treatment for obesity
* Have obesity induced by other endocrinological disorders or diagnosed monogenetic or syndromic forms of obesity
* Have renal impairment measured as estimated glomerular filtration rate (eGFR) \<30 milliliter (mL)/minute (min)/1.73 m²
* Have a history of acute chronic pancreatitis
* Have a history of significant active or unstable Major Depressive Disorder (MDD) or other severe psychiatric disorder (for example, schizophrenia, bipolar disorder, or other serious mood or anxiety disorder) within the last 2 years Note: Participants with MDD or generalized anxiety disorder whose disease state is considered stable for the past 2 years and expected to remain stable throughout the course of the study, may be considered for inclusion if they are not on excluded medications.

Within 3 months prior to screening:

* Have poorly controlled hypertension
* Have history of acute myocardial infarction
* Have history of cerebrovascular accident (stroke)
* Had hospitalization due to congestive heart failure (CHF)
* Have cancer
* Have human immunodeficiency virus (HIV) and/or positive HIV antibodies historically or at screening
* Have hepatitis B and/or positive hepatitis B surface antigen

**Maximum Age:** 75 Years

**Minimum Age:** 18 Years

**Sex:** ALL

**Standard Ages:**

- ADULT

- OLDER_ADULT

### Contacts Locations Module

#### Locations

**Location 1:**

**City:** Anaheim

**Country:** United States

**Facility:** Anaheim Clinical Trials, LLC

**State:** California

**Zip:** 92801

**Location 2:**

**City:** Concord

**Country:** United States

**Facility:** John Muir Physician Network Research Center

**State:** California

**Zip:** 94520

**Location 3:**

**City:** Greenbrae

**Country:** United States

**Facility:** NorCal Medical Research, Inc

**State:** California

**Zip:** 94904

**Location 4:**

**City:** Northridge

**Country:** United States

**Facility:** Valley Clinical Trials, Inc.

**State:** California

**Zip:** 91325

**Location 5:**

**City:** San Ramon

**Country:** United States

**Facility:** Norcal Endocrinology & Internal Medicine

**State:** California

**Zip:** 94583

**Location 6:**

**City:** Blackfoot

**Country:** United States

**Facility:** Elite Clinical Trials

**State:** Idaho

**Zip:** 83221

**Location 7:**

**City:** Idaho Falls

**Country:** United States

**Facility:** Rocky Mountain Clinical Research

**State:** Idaho

**Zip:** 83404

**Location 8:**

**City:** Saint Peters

**Country:** United States

**Facility:** StudyMetrix Research

**State:** Missouri

**Zip:** 63303

**Location 9:**

**City:** Trenton

**Country:** United States

**Facility:** Premier Research

**State:** New Jersey

**Zip:** 08611

**Location 10:**

**City:** Fargo

**Country:** United States

**Facility:** Lillestol Research

**State:** North Dakota

**Zip:** 58104

**Location 11:**

**City:** Norman

**Country:** United States

**Facility:** Intend Research, LLC

**State:** Oklahoma

**Zip:** 73069

**Location 12:**

**City:** Camp Hill

**Country:** United States

**Facility:** Capital Area Research, LLC

**State:** Pennsylvania

**Zip:** 17011

**Location 13:**

**City:** Pittsburgh

**Country:** United States

**Facility:** Preferred Primary Care Physicians, Preferred Clinical Research-St. Clair

**State:** Pennsylvania

**Zip:** 15243

**Location 14:**

**City:** Dallas

**Country:** United States

**Facility:** Dallas Diabetes Research Center

**State:** Texas

**Zip:** 75230

**Location 15:**

**City:** Fort Worth

**Country:** United States

**Facility:** Diabetes and Thyroid Center of Fort Worth

**State:** Texas

**Zip:** 76132

**Location 16:**

**City:** Round Rock

**Country:** United States

**Facility:** Texas Diabetes & Endocrinology, P.A.

**State:** Texas

**Zip:** 78681

**Location 17:**

**City:** Richmond

**Country:** United States

**Facility:** National Clinical Research, Inc

**State:** Virginia

**Zip:** 23294

**Location 18:**

**City:** Green Bay

**Country:** United States

**Facility:** St. Vincent Hospital d/b/a Prevea Health

**State:** Wisconsin

**Zip:** 54303

**Location 19:**

**City:** Calgary

**Country:** Canada

**Facility:** C-health Research

**State:** Alberta

**Zip:** T2V 4J2

**Location 20:**

**City:** Hamilton

**Country:** Canada

**Facility:** Wharton Medical Clinic

**State:** Ontario

**Zip:** L8L 5G8

**Location 21:**

**City:** Sarnia

**Country:** Canada

**Facility:** Bluewater Clinical Research Group Inc.

**State:** Ontario

**Zip:** N7T 4X3

**Location 22:**

**City:** Saint Marc des Carrières

**Country:** Canada

**Facility:** Centre Médical et Professionnel de l'Ouest de Portneuf

**State:** Quebec

**Zip:** G0A 4B0

**Location 23:**

**City:** Quebec

**Country:** Canada

**Facility:** Alpha Recherche Clinique

**Zip:** G2J 0C4

**Location 24:**

**City:** Quebec

**Country:** Canada

**Facility:** ALPHA Recherche Clinique

**Zip:** G3K 2P8

**Location 25:**

**City:** Kalocsa

**Country:** Hungary

**Facility:** Studium Egeszseghaz Kft

**State:** Bács-Kiskun

**Zip:** 6300

**Location 26:**

**City:** Gyongyos

**Country:** Hungary

**Facility:** Bugát Pál Kórház

**State:** Heves

**Zip:** 3200

**Location 27:**

**City:** Balatonfüred

**Country:** Hungary

**Facility:** DRC Gyógyszervizsgáló Központ

**State:** Veszprém

**Zip:** 8230

**Location 28:**

**City:** Nagykanizsa

**Country:** Hungary

**Facility:** Kanizsai Dorottya Korhaz

**State:** Zala

**Zip:** 8800

**Location 29:**

**City:** Budapest

**Country:** Hungary

**Facility:** Szent Margit Rendelőintézet Nonprofit Kft

**Zip:** 1032

**Location 30:**

**City:** Budapest

**Country:** Hungary

**Facility:** Clinexpert Kft.

**Zip:** 1033

**Location 31:**

**City:** Budapest

**Country:** Hungary

**Facility:** TRANTOR'99 Bt. Anyagcsere Centrum

**Zip:** 1213

**Location 32:**

**City:** Budapest

**Country:** Hungary

**Facility:** Strazsahegy Medicina Bt.

**Zip:** H1171

**Location 33:**

**City:** Debrecen

**Country:** Hungary

**Facility:** Debreceni Egyetem Klinikai Kozpont

**Zip:** 4032

**Location 34:**

**City:** Ponce

**Country:** Puerto Rico

**Facility:** Puerto Rico Medical Research

**Zip:** 00717

**Location 35:**

**City:** Ponce

**Country:** Puerto Rico

**Facility:** Research and Cardiovascular Corp.

**Zip:** 00717

#### Overall Officials

**Official 1:**

**Affiliation:** Eli Lilly and Company

**Name:** Call 1-877-CTLILLY (1-877-285-4559) or 1-317-5615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

**Role:** STUDY_DIRECTOR

### IPD Sharing Statement Module

**Access Criteria:** A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

**Description:** Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

**Info Types:**

- STUDY_PROTOCOL

- SAP

- CSR

**IPD Sharing:** YES

**Time Frame:** Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

**URL:** https://vivli.org/

### References Module

#### See Also Links

**Label:** A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities

**URL:** https://trials.lillytrialguide.com/en-US/trial/1R7BP1Yw5t6roV3ZWFGzYQ

## Document Section

### Large Document Module

#### Large Docs

- Date: 2021-09-27

- Filename: Prot_000.pdf

- Has ICF: False

- Has Protocol: True

- Has SAP: False

- Label: Study Protocol

- Size: 5864017

- Type Abbrev: Prot

- Upload Date: 2023-08-08T01:56

- Date: 2022-10-03

- Filename: SAP_001.pdf

- Has ICF: False

- Has Protocol: False

- Has SAP: True

- Label: Statistical Analysis Plan

- Size: 1191356

- Type Abbrev: SAP

- Upload Date: 2023-08-08T01:57

## Derived Section

### Condition Browse Module - Ancestors

- ID: D000044343

- Term: Overnutrition

- ID: D000009748

- Term: Nutrition Disorders

- ID: D000001835

- Term: Body Weight

### Condition Browse Module - Browse Branches

- Abbrev: BC23

- Name: Symptoms and General Pathology

- Abbrev: All

- Name: All Conditions

- Abbrev: BC18

- Name: Nutritional and Metabolic Diseases

### Condition Browse Module - Browse Leaves

- ID: M5114

- Name: Body Weight

- Relevance: LOW

- As Found: Unknown

- ID: M12701

- Name: Obesity

- Relevance: HIGH

- As Found: Obesity

- ID: M26186

- Name: Overweight

- Relevance: HIGH

- As Found: Overweight

- ID: M25307

- Name: Overnutrition

- Relevance: LOW

- As Found: Unknown

- ID: M12684

- Name: Nutrition Disorders

- Relevance: LOW

- As Found: Unknown

### Condition Browse Module - Meshes

- ID: D000009765

- Term: Obesity

- ID: D000050177

- Term: Overweight

### Misc Info Module

- Version Holder: 2024-05-24

## Results Section

### Adverse Events Module

**Description:** All randomized participants who received at least one dose of study drug regardless of adherence to study drug. Gender specific events occurring only in male or female participants have had the number of participants at risk adjusted accordingly.

#### Event Groups

**Group ID:** EG000

**Title:** 12 mg LY3502970

**Deaths Num At Risk:** 50

**Description:** Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks.

**ID:** EG000

**Other Num Affected:** 35

**Other Num at Risk:** 50

**Serious Number At Risk:** 50

**Title:** 12 mg LY3502970

**Group ID:** EG001

**Title:** 24 mg LY3502970

**Deaths Num At Risk:** 53

**Description:** Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks.

**ID:** EG001

**Other Num Affected:** 46

**Other Num at Risk:** 53

**Serious Number Affected:** 2

**Serious Number At Risk:** 53

**Title:** 24 mg LY3502970

**Group ID:** EG002

**Title:** 36 Mg-1 LY3502970

**Deaths Num At Risk:** 29

**Description:** Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.

**ID:** EG002

**Other Num Affected:** 23

**Other Num at Risk:** 29

**Serious Number At Risk:** 29

**Title:** 36 Mg-1 LY3502970

**Group ID:** EG003

**Title:** 36 Mg-2 LY3502970

**Deaths Num At Risk:** 29

**Description:** Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.

**ID:** EG003

**Other Num Affected:** 25

**Other Num at Risk:** 29

**Serious Number Affected:** 3

**Serious Number At Risk:** 29

**Title:** 36 Mg-2 LY3502970

**Group ID:** EG004

**Title:** 45 Mg-1 LY3502970

**Deaths Num At Risk:** 31

**Description:** Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.

**ID:** EG004

**Other Num Affected:** 26

**Other Num at Risk:** 31

**Serious Number Affected:** 2

**Serious Number At Risk:** 31

**Title:** 45 Mg-1 LY3502970

**Group ID:** EG005

**Title:** 45 Mg-2 LY3502970

**Deaths Num At Risk:** 30

**Description:** Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.

**ID:** EG005

**Other Num Affected:** 24

**Other Num at Risk:** 30

**Serious Number At Risk:** 30

**Title:** 45 Mg-2 LY3502970

**Group ID:** EG006

**Title:** Placebo

**Deaths Num At Risk:** 50

**Description:** Participants received placebo administered orally once daily until 36 weeks.

**ID:** EG006

**Other Num Affected:** 27

**Other Num at Risk:** 50

**Serious Number At Risk:** 50

**Title:** Placebo

**Frequency Threshold:** 5

#### Other Events

**Term:** Atrioventricular block first degree

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Cardiac disorders

**Source Vocabulary:** MedDRA 25.1

**Term:** Abdominal discomfort

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Gastrointestinal disorders

**Source Vocabulary:** MedDRA 25.1

**Term:** Abdominal distension

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Gastrointestinal disorders

**Source Vocabulary:** MedDRA 25.1

**Term:** Abdominal pain

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Gastrointestinal disorders

**Source Vocabulary:** MedDRA 25.1

**Term:** Abdominal pain upper

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Gastrointestinal disorders

**Source Vocabulary:** MedDRA 25.1

**Term:** Constipation

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Gastrointestinal disorders

**Source Vocabulary:** MedDRA 25.1

**Term:** Diarrhoea

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Gastrointestinal disorders

**Source Vocabulary:** MedDRA 25.1

**Term:** Dyspepsia

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Gastrointestinal disorders

**Source Vocabulary:** MedDRA 25.1

**Term:** Eructation

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Gastrointestinal disorders

**Source Vocabulary:** MedDRA 25.1

**Term:** Flatulence

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Gastrointestinal disorders

**Source Vocabulary:** MedDRA 25.1

**Term:** Gastrooesophageal reflux disease

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Gastrointestinal disorders

**Source Vocabulary:** MedDRA 25.1

**Term:** Nausea

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Gastrointestinal disorders

**Source Vocabulary:** MedDRA 25.1

**Term:** Vomiting

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Gastrointestinal disorders

**Source Vocabulary:** MedDRA 25.1

**Term:** Chills

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** General disorders

**Source Vocabulary:** MedDRA 25.1

**Term:** Fatigue

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** General disorders

**Source Vocabulary:** MedDRA 25.1

**Term:** Covid-19

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Infections and infestations

**Source Vocabulary:** MedDRA 25.1

**Term:** Nasopharyngitis

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Infections and infestations

**Source Vocabulary:** MedDRA 25.1

**Term:** Sinusitis

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Infections and infestations

**Source Vocabulary:** MedDRA 25.1

**Term:** Upper respiratory tract infection

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Infections and infestations

**Source Vocabulary:** MedDRA 25.1

**Term:** Urinary tract infection

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Infections and infestations

**Source Vocabulary:** MedDRA 25.1

**Term:** Decreased appetite

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Metabolism and nutrition disorders

**Source Vocabulary:** MedDRA 25.1

**Term:** Arthralgia

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Musculoskeletal and connective tissue disorders

**Source Vocabulary:** MedDRA 25.1

**Term:** Back pain

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Musculoskeletal and connective tissue disorders

**Source Vocabulary:** MedDRA 25.1

**Term:** Muscle spasms

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Musculoskeletal and connective tissue disorders

**Source Vocabulary:** MedDRA 25.1

**Term:** Myalgia

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Musculoskeletal and connective tissue disorders

**Source Vocabulary:** MedDRA 25.1

**Term:** Pain in extremity

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Musculoskeletal and connective tissue disorders

**Source Vocabulary:** MedDRA 25.1

**Term:** Dizziness

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Nervous system disorders

**Source Vocabulary:** MedDRA 25.1

**Term:** Headache

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Nervous system disorders

**Source Vocabulary:** MedDRA 25.1

**Term:** Dysuria

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Renal and urinary disorders

**Source Vocabulary:** MedDRA 25.1

**Term:** Balanoposthitis

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Reproductive system and breast disorders

**Source Vocabulary:** MedDRA 25.1

**Term:** Erectile dysfunction

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Reproductive system and breast disorders

**Source Vocabulary:** MedDRA 25.1

**Term:** Postmenopausal haemorrhage

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Reproductive system and breast disorders

**Source Vocabulary:** MedDRA 25.1

**Term:** Vulvovaginal pruritus

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Reproductive system and breast disorders

**Source Vocabulary:** MedDRA 25.1

**Term:** Oropharyngeal pain

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Respiratory, thoracic and mediastinal disorders

**Source Vocabulary:** MedDRA 25.1

**Term:** Alopecia

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Skin and subcutaneous tissue disorders

**Source Vocabulary:** MedDRA 25.1

**Term:** Hypotension

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Vascular disorders

**Source Vocabulary:** MedDRA 25.1

#### Serious Events

**Term:** Coronary artery disease

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Cardiac disorders

**Source Vocabulary:** MedDRA 25.1

##### Stats

**Group ID:** EG000

**Num At Risk:** 50

**Group ID:** EG001

**Num At Risk:** 53

**Group ID:** EG002

**Num At Risk:** 29

**Group ID:** EG003

**Num At Risk:** 29

**Group ID:** EG004

**Num Affected:** 1

**Num At Risk:** 31

**Num Events:** 1

**Group ID:** EG005

**Num At Risk:** 30

**Group ID:** EG006

**Num At Risk:** 50

**Term:** Retinal vein thrombosis

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Eye disorders

**Source Vocabulary:** MedDRA 25.1

##### Stats

**Group ID:** EG000

**Num At Risk:** 50

**Group ID:** EG001

**Num At Risk:** 53

**Group ID:** EG002

**Num At Risk:** 29

**Group ID:** EG003

**Num Affected:** 1

**Num At Risk:** 29

**Num Events:** 1

**Group ID:** EG004

**Num At Risk:** 31

**Group ID:** EG005

**Num At Risk:** 30

**Group ID:** EG006

**Num At Risk:** 50

**Term:** Vitreoretinal traction syndrome

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Eye disorders

**Source Vocabulary:** MedDRA 25.1

##### Stats

**Group ID:** EG000

**Num At Risk:** 50

**Group ID:** EG001

**Num At Risk:** 53

**Group ID:** EG002

**Num At Risk:** 29

**Group ID:** EG003

**Num At Risk:** 29

**Group ID:** EG004

**Num Affected:** 1

**Num At Risk:** 31

**Num Events:** 1

**Group ID:** EG005

**Num At Risk:** 30

**Group ID:** EG006

**Num At Risk:** 50

**Term:** Diverticulum intestinal

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Gastrointestinal disorders

**Source Vocabulary:** MedDRA 25.1

##### Stats

**Group ID:** EG000

**Num At Risk:** 50

**Group ID:** EG001

**Num At Risk:** 53

**Group ID:** EG002

**Num At Risk:** 29

**Group ID:** EG003

**Num Affected:** 1

**Num At Risk:** 29

**Num Events:** 1

**Group ID:** EG004

**Num At Risk:** 31

**Group ID:** EG005

**Num At Risk:** 30

**Group ID:** EG006

**Num At Risk:** 50

**Term:** Gastrointestinal polyp haemorrhage

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Gastrointestinal disorders

**Source Vocabulary:** MedDRA 25.1

##### Stats

**Group ID:** EG000

**Num At Risk:** 50

**Group ID:** EG001

**Num Affected:** 1

**Num At Risk:** 53

**Num Events:** 1

**Group ID:** EG002

**Num At Risk:** 29

**Group ID:** EG003

**Num At Risk:** 29

**Group ID:** EG004

**Num At Risk:** 31

**Group ID:** EG005

**Num At Risk:** 30

**Group ID:** EG006

**Num At Risk:** 50

**Term:** Cholecystitis acute

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Hepatobiliary disorders

**Source Vocabulary:** MedDRA 25.1

##### Stats

**Group ID:** EG000

**Num At Risk:** 50

**Group ID:** EG001

**Num Affected:** 1

**Num At Risk:** 53

**Num Events:** 1

**Group ID:** EG002

**Num At Risk:** 29

**Group ID:** EG003

**Num At Risk:** 29

**Group ID:** EG004

**Num At Risk:** 31

**Group ID:** EG005

**Num At Risk:** 30

**Group ID:** EG006

**Num At Risk:** 50

**Term:** Hypercalcaemia

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Metabolism and nutrition disorders

**Source Vocabulary:** MedDRA 25.1

##### Stats

**Group ID:** EG000

**Num At Risk:** 50

**Group ID:** EG001

**Num At Risk:** 53

**Group ID:** EG002

**Num At Risk:** 29

**Group ID:** EG003

**Num Affected:** 1

**Num At Risk:** 29

**Num Events:** 1

**Group ID:** EG004

**Num At Risk:** 31

**Group ID:** EG005

**Num At Risk:** 30

**Group ID:** EG006

**Num At Risk:** 50

**Term:** Hepatic cancer metastatic

**Assessment Type:** SYSTEMATIC_ASSESSMENT

**Organ System:** Neoplasms benign, malignant and unspecified (incl cysts and polyps)

**Source Vocabulary:** MedDRA 25.1

##### Stats

**Group ID:** EG000

**Num At Risk:** 50

**Group ID:** EG001

**Num At Risk:** 53

**Group ID:** EG002

**Num At Risk:** 29

**Group ID:** EG003

**Num Affected:** 1

**Num At Risk:** 29

**Num Events:** 1

**Group ID:** EG004

**Num At Risk:** 31

**Group ID:** EG005

**Num At Risk:** 30

**Group ID:** EG006

**Num At Risk:** 50

**Time Frame:** Baseline through Week 38 (36 weeks with 2 weeks safety follow up)

## Results Section - Baseline Characteristics Module

### Denomination Counts

**Group ID:** BG000

**Value:** 50

**Group ID:** BG001

**Value:** 53

**Group ID:** BG002

**Value:** 29

**Group ID:** BG003

**Value:** 29

**Group ID:** BG004

**Value:** 31

**Group ID:** BG005

**Value:** 30

**Group ID:** BG006

**Value:** 50

**Group ID:** BG007

**Value:** 272

**Units:** Participants

### Group

**ID:** BG000

**Title:** 12 mg LY3502970

**Description:** Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks.

### Group

**ID:** BG001

**Title:** 24 mg LY3502970

**Description:** Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks.

### Group

**ID:** BG002

**Title:** 36 mg -1 LY3502970

**Description:** Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.

### Group

**ID:** BG003

**Title:** 36 mg -2 LY3502970

**Description:** Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.

### Group

**ID:** BG004

**Title:** 45 mg -1 LY3502970

**Description:** Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.

### Group

**ID:** BG005

**Title:** 45 mg -2 LY3502970

**Description:** Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.

### Group

**ID:** BG006

**Title:** Placebo

**Description:** Participants received placebo administered orally once daily until 36 weeks.

### Group

**ID:** BG007

**Title:** Total

**Description:** Total of all reporting groups

### Measure

#### Measurement

**Group ID:** BG000

**Spread:** 10.51

**Value:** 49.80

#### Measurement

**Group ID:** BG001

**Spread:** 9.09

**Value:** 57.00

#### Measurement

**Group ID:** BG002

**Spread:** 11.83

**Value:** 56.30

#### Measurement

**Group ID:** BG003

**Spread:** 10.93

**Value:** 55.40

#### Measurement

**Group ID:** BG004

**Spread:** 10.74

**Value:** 56.50

#### Measurement

**Group ID:** BG005

**Spread:** 12.58

**Value:** 50.90

#### Measurement

**Group ID:** BG006

**Spread:** 8.82

**Value:** 54.00

#### Measurement

**Group ID:** BG007

**Spread:** 10.67

**Value:** 54.20

**Class Title:** 

### Measure

#### Measurement

**Group ID:** BG000

**Value:** 31

#### Measurement

**Group ID:** BG001

**Value:** 30

#### Measurement

**Group ID:** BG002

**Value:** 18

#### Measurement

**Group ID:** BG003

**Value:** 18

#### Measurement

**Group ID:** BG004

**Value:** 19

#### Measurement

**Group ID:** BG005

**Value:** 16

#### Measurement

**Group ID:** BG006

**Value:** 29

#### Measurement

**Group ID:** BG007

**Value:** 161

**Category Title:** Female

#### Measurement

**Group ID:** BG000

**Value:** 19

#### Measurement

**Group ID:** BG001

**Value:** 23

#### Measurement

**Group ID:** BG002

**Value:** 11

#### Measurement

**Group ID:** BG003

**Value:** 11

#### Measurement

**Group ID:** BG004

**Value:** 12

#### Measurement

**Group ID:** BG005

**Value:** 14

#### Measurement

**Group ID:** BG006

**Value:** 21

#### Measurement

**Group ID:** BG007

**Value:** 111

**Category Title:** Male

**Class Title:** 

### Measure

#### Measurement

**Group ID:** BG000

**Value:** 11

#### Measurement

**Group ID:** BG001

**Value:** 6

#### Measurement

**Group ID:** BG002

**Value:** 4

#### Measurement

**Group ID:** BG003

**Value:** 2

#### Measurement

**Group ID:** BG004

**Value:** 4

#### Measurement

**Group ID:** BG005

**Value:** 7

#### Measurement

**Group ID:** BG006

**Value:** 5

#### Measurement

**Group ID:** BG007

**Value:** 39

**Category Title:** Hispanic or Latino

#### Measurement

**Group ID:** BG000

**Value:** 38

#### Measurement

**Group ID:** BG001

**Value:** 46

#### Measurement

**Group ID:** BG002

**Value:** 23

#### Measurement

**Group ID:** BG003

**Value:** 26

#### Measurement

**Group ID:** BG004

**Value:** 25

#### Measurement

**Group ID:** BG005

**Value:** 22

#### Measurement

**Group ID:** BG006

**Value:** 43

#### Measurement

**Group ID:** BG007

**Value:** 223

**Category Title:** Not Hispanic or Latino

#### Measurement

**Group ID:** BG000

**Value:** 1

#### Measurement

**Group ID:** BG001

**Value:** 1

#### Measurement

**Group ID:** BG002

**Value:** 2

#### Measurement

**Group ID:** BG003

**Value:** 1

#### Measurement

**Group ID:** BG004

**Value:** 2

#### Measurement

**Group ID:** BG005

**Value:** 1

#### Measurement

**Group ID:** BG006

**Value:** 2

#### Measurement

**Group ID:** BG007

**Value:** 10

**Category Title:** Unknown or Not Reported

**Class Title:** 

### Measure

#### Measurement

**Group ID:** BG000

**Value:** 0

#### Measurement

**Group ID:** BG001

**Value:** 1

#### Measurement

**Group ID:** BG002

**Value:** 0

#### Measurement

**Group ID:** BG003

**Value:** 0

#### Measurement

**Group ID:** BG004

**Value:** 0

#### Measurement

**Group ID:** BG005

**Value:** 0

#### Measurement

**Group ID:** BG006

**Value:** 0

#### Measurement

**Group ID:** BG007

**Value:** 1

**Category Title:** American Indian or Alaska Native

#### Measurement

**Group ID:** BG000

**Value:** 0

#### Measurement

**Group ID:** BG001

**Value:** 0

#### Measurement

**Group ID:** BG002

**Value:** 0

#### Measurement

**Group ID:** BG003

**Value:** 0

#### Measurement

**Group ID:** BG004

**Value:** 0

#### Measurement

**Group ID:** BG005

**Value:** 0

#### Measurement

**Group ID:** BG006

**Value:** 2

#### Measurement

**Group ID:** BG007

**Value:** 2

**Category Title:** Asian

#### Measurement

**Group ID:** BG000

**Value:** 0

#### Measurement

**Group ID:** BG001

**Value:** 0

#### Measurement

**Group ID:** BG002

**Value:** 0

#### Measurement

**Group ID:** BG003

**Value:** 0

#### Measurement

**Group ID:** BG004

**Value:** 0

#### Measurement

**Group ID:** BG005

**Value:** 0

#### Measurement

**Group ID:** BG006

**Value:** 0

#### Measurement

**Group ID:** BG007

**Value:** 0

**Category Title:** Native Hawaiian or Other Pacific Islander

#### Measurement

**Group ID:** BG000

**Value:** 3

#### Measurement

**Group ID:** BG001

**Value:** 6

#### Measurement

**Group ID:** BG002

**Value:** 4

#### Measurement

**Group ID:** BG003

**Value:** 4

#### Measurement

**Group ID:** BG004

**Value:** 1

#### Measurement

**Group ID:** BG005

**Value:** 0

#### Measurement

**Group ID:** BG006

**Value:** 1

#### Measurement

**Group ID:** BG007

**Value:** 19

**Category Title:** Black or African American

#### Measurement

**Group ID:** BG000

**Value:** 47

#### Measurement

**Group ID:** BG001

**Value:** 46

#### Measurement

**Group ID:** BG002

**Value:** 25

#### Measurement

**Group ID:** BG003

**Value:** 25

#### Measurement

**Group ID:** BG004

**Value:** 29

#### Measurement

**Group ID:** BG005

**Value:** 30

#### Measurement

**Group ID:** BG006

**Value:** 45

#### Measurement

**Group ID:** BG007

**Value:** 247

**Category Title:** White

#### Measurement

**Group ID:** BG000

**Value:** 0

#### Measurement

**Group ID:** BG001

**Value:** 0

#### Measurement

**Group ID:** BG002

**Value:** 0

#### Measurement

**Group ID:** BG003

**Value:** 0

#### Measurement

**Group ID:** BG004

**Value:** 0

#### Measurement

**Group ID:** BG005

**Value:** 0

#### Measurement

**Group ID:** BG006

**Value:** 2

#### Measurement

**Group ID:** BG007

**Value:** 2

**Category Title:** More than one race

#### Measurement

**Group ID:** BG000

**Value:** 0

#### Measurement

**Group ID:** BG001

**Value:** 0

#### Measurement

**Group ID:** BG002

**Value:** 0

#### Measurement

**Group ID:** BG003

**Value:** 0

#### Measurement

**Group ID:** BG004

**Value:** 1

#### Measurement

**Group ID:** BG005

**Value:** 0

#### Measurement

**Group ID:** BG006

**Value:** 0

#### Measurement

**Group ID:** BG007

**Value:** 1

**Category Title:** Unknown or Not Reported

**Class Title:** 

### Measure

#### Measurement

**Group ID:** BG000

**Value:** 9

#### Measurement

**Group ID:** BG001

**Value:** 11

#### Measurement

**Group ID:** BG002

**Value:** 5

#### Measurement

**Group ID:** BG003

**Value:** 3

#### Measurement

**Group ID:** BG004

**Value:** 9

#### Measurement

**Group ID:** BG005

**Value:** 5

#### Measurement

**Group ID:** BG006

**Value:** 6

#### Measurement

**Group ID:** BG007

**Value:** 48

**Class Title:** Canada

#### Measurement

**Group ID:** BG000

**Value:** 6

#### Measurement

**Group ID:** BG001

**Value:** 5

#### Measurement

**Group ID:** BG002

**Value:** 3

#### Measurement

**Group ID:** BG003

**Value:** 6

#### Measurement

**Group ID:** BG004

**Value:** 3

#### Measurement

**Group ID:** BG005

**Value:** 3

#### Measurement

**Group ID:** BG006

**Value:** 5

#### Measurement

**Group ID:** BG007

**Value:** 31

**Class Title:** Hungary

#### Measurement

**Group ID:** BG000

**Value:** 35

#### Measurement

**Group ID:** BG001

**Value:** 37

#### Measurement

**Group ID:** BG002

**Value:** 21

#### Measurement

**Group ID:** BG003

**Value:** 20

#### Measurement

**Group ID:** BG004

**Value:** 19

#### Measurement

**Group ID:** BG005

**Value:** 22

#### Measurement

**Group ID:** BG006

**Value:** 39

#### Measurement

**Group ID:** BG007

**Value:** 193

**Class Title:** United States

### Measure

#### Measurement

**Group ID:** BG000

**Spread:** 25.34

**Value:** 107.49

#### Measurement

**Group ID:** BG001

**Spread:** 30.18

**Value:** 112.05

#### Measurement

**Group ID:** BG002

**Spread:** 22.45

**Value:** 107.78

#### Measurement

**Group ID:** BG003

**Spread:** 28.52

**Value:** 108.84

#### Measurement

**Group ID:** BG004

**Spread:** 20.40

**Value:** 105.23

#### Measurement

**Group ID:** BG005

**Spread:** 28.11

**Value:** 110.85

#### Measurement

**Group ID:** BG006

**Spread:** 25.24

**Value:** 107.57

#### Measurement

**Group ID:** BG007

**Spread:** 26.03

**Value:** 108.68

**Class Title:** 

**Denomination Units Selected:** 

## Results Section - Baseline Characteristics Module

### Measure 1
**Dispersion Type:** STANDARD_DEVIATION
**Parameter Type:** MEAN
**Title:** Age, Continuous
**Unit of Measure:** years
### Measure 2
**Parameter Type:** COUNT_OF_PARTICIPANTS
**Title:** Sex: Female, Male
**Unit of Measure:** Participants
### Measure 3
**Parameter Type:** COUNT_OF_PARTICIPANTS
**Title:** Ethnicity (NIH/OMB)
**Unit of Measure:** Participants
### Measure 4
**Parameter Type:** COUNT_OF_PARTICIPANTS
**Title:** Race (NIH/OMB)
**Unit of Measure:** Participants
### Measure 5
**Parameter Type:** COUNT_OF_PARTICIPANTS
**Title:** Region of Enrollment
**Unit of Measure:** Participants
### Measure 6
**Dispersion Type:** STANDARD_DEVIATION
**Parameter Type:** MEAN
**Title:** Baseline Body Weight
**Unit of Measure:** Kilograms (kg)
**Population Description:** All randomized participants.
## Results Section - More Information Module
### Certain Agreement
**Restriction Type:** GT60
**Restrictive Agreement:** True
### Point of Contact
**Email:** ClinicalTrials.gov@lilly.com
**Organization:** Eli Lilly and Company
**Phone:** 800-545-5979
**Title:** Chief Medical Officer
## Results Section - Outcome Measures Module
### Outcome Measure 1
#### Analysis
**CI Lower Limit:** -8.9
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** -4.2
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** SUPERIORITY
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** LS Mean difference (Final Values)
**Parameter Value:** -6.5
**Statistical Comment:** 
**Statistical Method:** Mixed Models Analysis
**Tested Non-Inferiority:** 
#### Analysis
**CI Lower Limit:** -11.5
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** -6.9
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** SUPERIORITY
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** LS Mean difference (Final Values)
**Parameter Value:** -9.2
**Statistical Comment:** 
**Statistical Method:** Mixed Models Analysis
**Tested Non-Inferiority:** 
#### Analysis
**CI Lower Limit:** -12.4
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** -8.0
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** SUPERIORITY
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** LS Mean difference (Final Values)
**Parameter Value:** -10.2
**Statistical Comment:** 
**Statistical Method:** Mixed Models Analysis
**Tested Non-Inferiority:** 
#### Analysis
**CI Lower Limit:** -12.7
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** -8.4
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** SUPERIORITY
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** LS Mean difference (Final Values)
**Parameter Value:** -10.6
**Statistical Comment:** 
**Statistical Method:** Mixed Models Analysis
**Tested Non-Inferiority:** 
### Outcome Measure 2
#### Analysis
**CI Lower Limit:** -9.9
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** -4.2
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** LS Mean difference (Final Values)
**Parameter Value:** -7.1
**Statistical Comment:** 
**Statistical Method:** Mixed Models Analysis
**Tested Non-Inferiority:** 
#### Analysis
**CI Lower Limit:** -12.9
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** -7.3
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** LS Mean difference (Final Values)
**Parameter Value:** -10.1
**Statistical Comment:** 
**Statistical Method:** Mixed Models Analysis
**Tested Non-Inferiority:** 
#### Analysis
**CI Lower Limit:** -13.8
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** -8.4
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** LS Mean difference (Final Values)
**Parameter Value:** -11.1
**Statistical Comment:** 
**Statistical Method:** Mixed Models Analysis
**Tested Non-Inferiority:** 
#### Analysis
**CI Lower Limit:** -15.0
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** -9.6
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** LS Mean difference (Final Values)
**Parameter Value:** -12.3
**Statistical Comment:** 
**Statistical Method:** Mixed Models Analysis
**Tested Non-Inferiority:** 
### Outcome Measure 3
#### Analysis
**CI Lower Limit:** -9.3
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** -4.4
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** LS Mean difference (Final Values)
**Parameter Value:** -6.9
**Statistical Comment:** 
**Statistical Method:** Mixed Models Analysis
**Tested Non-Inferiority:** 
#### Analysis
**CI Lower Limit:** -12.5
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** -7.8
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** LS Mean difference (Final Values)
**Parameter Value:** -10.2
**Statistical Comment:** 
**Statistical Method:** Mixed Models Analysis
**Tested Non-Inferiority:** 
#### Analysis
**CI Lower Limit:** -13.1
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** -8.5
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** LS Mean difference (Final Values)
**Parameter Value:** -10.8
**Statistical Comment:** 
**Statistical Method:** Mixed Models Analysis
**Tested Non-Inferiority:** 
#### Analysis
**CI Lower Limit:** -13.5
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** -8.9
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** LS Mean difference (Final Values)
**Parameter Value:** -11.2
**Statistical Comment:** 
**Statistical Method:** Mixed Models Analysis
**Tested Non-Inferiority:** 
### Outcome Measure 4
#### Analysis
**CI Lower Limit:** -10.4
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** -4.3
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** LS Mean difference (Final Values)
**Parameter Value:** -7.4
**Statistical Comment:** 
**Statistical Method:** Mixed Models Analysis
**Tested Non-Inferiority:** 
#### Analysis
**CI Lower Limit:** -14.2
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** -8.3
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** LS Mean difference (Final Values)
**Parameter Value:** -11.2
**Statistical Comment:** 
**Statistical Method:** Mixed Models Analysis
**Tested Non-Inferiority:** 
#### Analysis
**CI Lower Limit:** -14.7
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** -9.0
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** LS Mean difference (Final Values)
**Parameter Value:** -11.8
**Statistical Comment:** 
**Statistical Method:** Mixed Models Analysis
**Tested Non-Inferiority:** 
#### Analysis
**CI Lower Limit:** -15.8
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** -10.2
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** LS Mean difference (Final Values)
**Parameter Value:** -13.0
**Statistical Comment:** 
**Statistical Method:** Mixed Models Analysis
**Tested Non-Inferiority:** 
### Outcome Measure 5
#### Analysis
**CI Lower Limit:** -7.2
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** -1.6
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** 0.002
**P-Value Comment:** 
**Parameter Type:** LS Mean difference (Final Values)
**Parameter Value:** -4.4
**Statistical Comment:** 
**Statistical Method:** Mixed Models Analysis
**Tested Non-Inferiority:** 
#### Analysis
**CI Lower Limit:** -8.0
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** -2.4
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** LS Mean difference (Final Values)
**Parameter Value:** -5.2
**Statistical Comment:** 
**Statistical Method:** Mixed Models Analysis
**Tested Non-Inferiority:** 
#### Analysis
**CI Lower Limit:** -9.2
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** -3.8
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** LS Mean difference (Final Values)
**Parameter Value:** -6.5
**Statistical Comment:** 
**Statistical Method:** Mixed Models Analysis
**Tested Non-Inferiority:** 
#### Analysis
**CI Lower Limit:** -11.3
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** -6.0
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** LS Mean difference (Final Values)
**Parameter Value:** -8.7
**Statistical Comment:** 
**Statistical Method:** Mixed Models Analysis
**Tested Non-Inferiority:** 
### Outcome Measure 6
#### Analysis
**CI Lower Limit:** -8.8
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** -2.4
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** LS Mean difference (Final Values)
**Parameter Value:** -5.6
**Statistical Comment:** 
**Statistical Method:** Mixed Models Analysis
**Tested Non-Inferiority:** 
#### Analysis
**CI Lower Limit:** -10.3
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** -4.0
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** LS Mean difference (Final Values)
**Parameter Value:** -7.2
**Statistical Comment:** 
**Statistical Method:** Mixed Models Analysis
**Tested Non-Inferiority:** 
#### Analysis
**CI Lower Limit:** -9.7
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** -3.6
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** LS Mean difference (Final Values)
**Parameter Value:** -6.6
**Statistical Comment:** 
**Statistical Method:** Mixed Models Analysis
**Tested Non-Inferiority:** 
#### Analysis
**CI Lower Limit:** -12.7
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** -6.6
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** LS Mean difference (Final Values)
**Parameter Value:** -9.6
**Statistical Comment:** 
**Statistical Method:** Mixed Models Analysis
**Tested Non-Inferiority:** 
### Outcome Measure 7
#### Analysis
**CI Lower Limit:** -3.2
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** -1.6
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** LS Mean difference (Final Values)
**Parameter Value:** -2.4
**Statistical Comment:** 
**Statistical Method:** Mixed Models Analysis
**Tested Non-Inferiority:** 
#### Analysis
**CI Lower Limit:** -4.3
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** -2.6
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** LS Mean difference (Final Values)
**Parameter Value:** -3.5
**Statistical Comment:** 
**Statistical Method:** Mixed Models Analysis
**Tested Non-Inferiority:** 
#### Analysis
**CI Lower Limit:** -4.6
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** 3.0
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** LS Mean difference (Final Values)
**Parameter Value:** -3.8
**Statistical Comment:** 
**Statistical Method:** Mixed Models Analysis
**Tested Non-Inferiority:** 
#### Analysis
**CI Lower Limit:** -4.7
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** -3.1
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** LS Mean difference (Final Values)
**Parameter Value:** -3.9
**Statistical Comment:** 
**Statistical Method:** Mixed Models Analysis
**Tested Non-Inferiority:** 
### Outcome Measure 8
#### Analysis
**CI Lower Limit:** -3.6
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** -1.5
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** LS Mean difference (Final Values)
**Parameter Value:** -2.5
**Statistical Comment:** 
**Statistical Method:** Mixed Models Analysis
**Tested Non-Inferiority:** 
#### Analysis
**CI Lower Limit:** -4.8
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** -2.8
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** LS Mean difference (Final Values)
**Parameter Value:** -3.8
**Statistical Comment:** 
**Statistical Method:** Mixed Models Analysis
**Tested Non-Inferiority:** 
#### Analysis
**CI Lower Limit:** -5.2
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** -3.2
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** LS Mean difference (Final Values)
**Parameter Value:** -4.2
**Statistical Comment:** 
**Statistical Method:** Mixed Models Analysis
**Tested Non-Inferiority:** 
#### Analysis
**CI Lower Limit:** -5.6
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** -3.6
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** LS Mean difference (Final Values)
**Parameter Value:** -4.6
**Statistical Comment:** 
**Statistical Method:** Mixed Models Analysis
**Tested Non-Inferiority:** 
### Outcome Measure 9
#### Analysis
**CI Lower Limit:** 3.61
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** 27.44
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** Odds Ratio (OR)
**Parameter Value:** 9.96
**Statistical Comment:** 
**Statistical Method:** Regression, Logistic
**Tested Non-Inferiority:** 
#### Analysis
**CI Lower Limit:** 8.15
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** 96.01
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** Odds Ratio (OR)
**Parameter Value:** 27.97
**Statistical Comment:** 
**Statistical Method:** Regression, Logistic
**Tested Non-Inferiority:** 
#### Analysis
**CI Lower Limit:** 8.71
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** 85.91
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** Odds Ratio (OR)
**Parameter Value:** 27.36
**Statistical Comment:** 
**Statistical Method:** Regression, Logistic
**Tested Non-Inferiority:** 
#### Analysis
**CI Lower Limit:** 7.65
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** 72.77
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** Odds Ratio (OR)
**Parameter Value:** 23.59
**Statistical Comment:** 
**Statistical Method:** Regression, Logistic
**Tested Non-Inferiority:** 
### Outcome Measure 10
#### Analysis
**CI Lower Limit:** 3.47
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** 114.40
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** Odds Ratio (OR)
**Parameter Value:** 19.93
**Statistical Comment:** 
**Statistical Method:** Regression, Logistic
**Tested Non-Inferiority:** 
#### Analysis
**CI Lower Limit:** 6.95
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** 224.83
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** Odds Ratio (OR)
**Parameter Value:** 39.52
**Statistical Comment:** 
**Statistical Method:** Regression, Logistic
**Tested Non-Inferiority:** 
#### Analysis
**CI Lower Limit:** 13.16
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** 427.18
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** Odds Ratio (OR)
**Parameter Value:** 74.97
**Statistical Comment:** 
**Statistical Method:** Regression, Logistic
**Tested Non-Inferiority:** 
#### Analysis
**CI Lower Limit:** 12.62
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** 413.21
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** Odds Ratio (OR)
**Parameter Value:** 72.23
**Statistical Comment:** 
**Statistical Method:** Regression, Logistic
**Tested Non-Inferiority:** 
### Outcome Measure 11
#### Analysis
**CI Lower Limit:** 2.90
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** 20.92
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** Odds Ratio (OR)
**Parameter Value:** 7.79
**Statistical Comment:** 
**Statistical Method:** Regression, Logistic
**Tested Non-Inferiority:** 
#### Analysis
**CI Lower Limit:** 7.49
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** 83.91
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** Odds Ratio (OR)
**Parameter Value:** 25.07
**Statistical Comment:** 
**Statistical Method:** Regression, Logistic
**Tested Non-Inferiority:** 
#### Analysis
**CI Lower Limit:** 8.17
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** 147.86
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** Odds Ratio (OR)
**Parameter Value:** 34.76
**Statistical Comment:** 
**Statistical Method:** Regression, Logistic
**Tested Non-Inferiority:** 
#### Analysis
**CI Lower Limit:** 8.15
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** 96.29
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** Odds Ratio (OR)
**Parameter Value:** 28.01
**Statistical Comment:** 
**Statistical Method:** Regression, Logistic
**Tested Non-Inferiority:** 
### Outcome Measure 12
#### Analysis
**CI Lower Limit:** 2.59
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** 26.45
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** Odds Ratio (OR)
**Parameter Value:** 8.27
**Statistical Comment:** 
**Statistical Method:** Regression, Logistic
**Tested Non-Inferiority:** 
#### Analysis
**CI Lower Limit:** 4.83
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** 50.68
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** Odds Ratio (OR)
**Parameter Value:** 15.64
**Statistical Comment:** 
**Statistical Method:** Regression, Logistic
**Tested Non-Inferiority:** 
#### Analysis
**CI Lower Limit:** 8.39
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** 88.38
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** Odds Ratio (OR)
**Parameter Value:** 27.24
**Statistical Comment:** 
**Statistical Method:** Regression, Logistic
**Tested Non-Inferiority:** 
#### Analysis
**CI Lower Limit:** 6.59
**CI Number of Sides:** TWO_SIDED
**CI Percentage Value:** 95
**CI Upper Limit:** 66.17
**CI Upper Limit Comment:** 
**Dispersion Type:** 
**Dispersion Value:** 
**Estimate Comment:** 
**Group Description:** 
**Non-Inferiority Comment:** 
**Non-Inferiority Type:** OTHER
**Other Analysis Description:** 
**P-Value:** <0.001
**P-Value Comment:** 
**Parameter Type:** Odds Ratio (OR)
**Parameter Value:** 20.88
**Statistical Comment:** 
**Statistical Method:** Regression, Logistic
**Tested Non-Inferiority:** 
## Results Section
### Outcome Measures Module
#### Outcome Measure 1
**Class:**
##### Category
**Measurements:**
- **Comment:** 
- **Group ID:** OG000
- **Lower Limit:** 
- **Spread:** 0.85
- **Upper Limit:** 
- **Value:** -8.6
- **Comment:** 
- **Group ID:** OG001
- **Lower Limit:** 
- **Spread:** 0.82
- **Upper Limit:** 
- **Value:** -11.2
- **Comment:** 
- **Group ID:** OG002
- **Lower Limit:** 
- **Spread:** 0.77
- **Upper Limit:** 
- **Value:** -12.3
- **Comment:** 
- **Group ID:** OG003
- **Lower Limit:** 
- **Spread:** 0.75
- **Upper Limit:** 
- **Value:** -12.6
- **Comment:** 
- **Group ID:** OG004
- **Lower Limit:** 
- **Spread:** 0.81
- **Upper Limit:** 
- **Value:** -2.0
**Title:** 
#### Outcome Measure 2
**Class:**
##### Category
**Measurements:**
- **Comment:** 
- **Group ID:** OG000
- **Lower Limit:** 
- **Spread:** 1.05
- **Upper Limit:** 
- **Value:** -9.4
- **Comment:** 
- **Group ID:** OG001
- **Lower Limit:** 
- **Spread:** 1.01
- **Upper Limit:** 
- **Value:** -12.5
- **Comment:** 
- **Group ID:** OG002
- **Lower Limit:** 
- **Spread:** 0.95
- **Upper Limit:** 
- **Value:** -13.5
- **Comment:** 
- **Group ID:** OG003
- **Lower Limit:** 
- **Spread:** 0.94
- **Upper Limit:** 
- **Value:** -14.7
- **Comment:** 
- **Group ID:** OG004
- **Lower Limit:** 
- **Spread:** 1.00
- **Upper Limit:** 
- **Value:** -2.3
**Title:** 
#### Outcome Measure 3
**Class:**
##### Category
**Measurements:**
- **Comment:** 
- **Group ID:** OG000
- **Lower Limit:** 
- **Spread:** 0.90
- **Upper Limit:** 
- **Value:** -9.0
- **Comment:** 
- **Group ID:** OG001
- **Lower Limit:** 
- **Spread:** 0.86
- **Upper Limit:** 
- **Value:** -12.3
- **Comment:** 
- **Group ID:** OG002
- **Lower Limit:** 
- **Spread:** 0.82
- **Upper Limit:** 
- **Value:** -12.9
- **Comment:** 
- **Group ID:** OG003
- **Lower Limit:** 
- **Spread:** 0.79
- **Upper Limit:** 
- **Value:** -13.3
- **Comment:** 
- **Group ID:** OG004
- **Lower Limit:** 
- **Spread:** 0.86
- **Upper Limit:** 
- **Value:** -2.1
**Title:** 
#### Outcome Measure 4
**Class:**
##### Category
**Measurements:**
- **Comment:** 
- **Group ID:** OG000
- **Lower Limit:** 
- **Spread:** 1.10
- **Upper Limit:** 
- **Value:** -9.8
- **Comment:** 
- **Group ID:** OG001
- **Lower Limit:** 
- **Spread:** 1.06
- **Upper Limit:** 
- **Value:** -13.6
- **Comment:** 
- **Group ID:** OG002
- **Lower Limit:** 
- **Spread:** 1.00
- **Upper Limit:** 
- **Value:** -14.2
- **Comment:** 
- **Group ID:** OG003
- **Lower Limit:** 
- **Spread:** 0.98
- **Upper Limit:** 
- **Value:** -15.4
- **Comment:** 
- **Group ID:** OG004
- **Lower Limit:** 
- **Spread:** 1.05
- **Upper Limit:** 
- **Value:** -2.4
**Title:** 
#### Outcome Measure 5
**Class:**
##### Category
**Measurements:**
- **Comment:** 
- **Group ID:** OG000
- **Lower Limit:** 
- **Spread:** 1.03
- **Upper Limit:** 
- **Value:** -8.0
- **Comment:** 
- **Group ID:** OG001
- **Lower Limit:** 
- **Spread:** 1.00
- **Upper Limit:** 
- **Value:** -8.8
- **Comment:** 
- **Group ID:** OG002
- **Lower Limit:** 
- **Spread:** 0.94
- **Upper Limit:** 
- **Value:** -10.1
- **Comment:** 
- **Group ID:** OG003
- **Lower Limit:** 
- **Spread:** 0.93
- **Upper Limit:** 
- **Value:** -12.2
- **Comment:** 
- **Group ID:** OG004
- **Lower Limit:** 
- **Spread:** 0.99
- **Upper Limit:** 
- **Value:** -3.6
**Title:** 
#### Outcome Measure 6
**Class:**
##### Category
**Measurements:**
- **Comment:** 
- **Group ID:** OG000
- **Lower Limit:** 
- **Spread:** 1.18
- **Upper Limit:** 
- **Value:** -9.6
- **Comment:** 
- **Group ID:** OG001
- **Lower Limit:** 
- **Spread:** 1.15
- **Upper Limit:** 
- **Value:** -11.2
- **Comment:** 
- **Group ID:** OG002
- **Lower Limit:** 
- **Spread:** 1.06
- **Upper Limit:** 
- **Value:** -10.6
- **Comment:** 
- **Group ID:** OG003
- **Lower Limit:** 
- **Spread:** 1.07
- **Upper Limit:** 
- **Value:** -13.6
- **Comment:** 
- **Group ID:** OG004
- **Lower Limit:** 
- **Spread:** 1.12
- **Upper Limit:** 
- **Value:** -4.0
**Title:** 
#### Outcome Measure 7
**Class:**
##### Category
**Measurements:**
- **Comment:** 
- **Group ID:** OG000
- **Lower Limit:** 
- **Spread:** 0.31
- **Upper Limit:** 
- **Value:** -3.2
- **Comment:** 
- **Group ID:** OG001
- **Lower Limit:** 
- **Spread:** 0.30
- **Upper Limit:** 
- **Value:** -4.2
- **Comment:** 
- **Group ID:** OG002
- **Lower Limit:** 
- **Spread:** 0.28
- **Upper Limit:** 
- **Value:** -4.6
- **Comment:** 
- **Group ID:** OG003
- **Lower Limit:** 
- **Spread:** 0.27
- **Upper Limit:** 
- **Value:** -4.7
- **Comment:** 
- **Group ID:** OG004
- **Lower Limit:** 
- **Spread:** 0.29
- **Upper Limit:** 
- **Value:** -0.8
**Title:** 
#### Outcome Measure 8
**Class:**
##### Category
**Measurements:**
- **Comment:** 
- **Group ID:** OG000
- **Lower Limit:** 
- **Spread:** 0.38
- **Upper Limit:** 
- **Value:** -3.4
- **Comment:** 
- **Group ID:** OG001
- **Lower Limit:** 
- **Spread:** 0.36
- **Upper Limit:** 
- **Value:** -4.7
- **Comment:** 
- **Group ID:** OG002
- **Lower Limit:** 
- **Spread:** 0.34
- **Upper Limit:** 
- **Value:** -5.0
- **Comment:** 
- **Group ID:** OG003
- **Lower Limit:** 
- **Spread:** 0.34
- **Upper Limit:** 
- **Value:** -5.5
- **Comment:** 
- **Group ID:** OG004
- **Lower Limit:** 
- **Spread:** 0.36
- **Upper Limit:** 
- **Value:** -0.9
**Title:** 
#### Outcome Measure 9
**Class:**
##### Category
**Measurements:**
- **Comment:** 
- **Group ID:** OG000
- **Lower Limit:** 
- **Spread:** 
- **Upper Limit:** 
- **Value:** 74.39
- **Comment:** 
- **Group ID:** OG001
- **Lower Limit:** 
- **Spread:** 
- **Upper Limit:** 
- **Value:** 88.84
- **Comment:** 
- **Group ID:** OG002
- **Lower Limit:** 
- **Spread:** 
- **Upper Limit:** 
- **Value:** 89.46
- **Comment:** 
- **Group ID:** OG003
- **Lower Limit:** 
- **Spread:** 
- **Upper Limit:** 
- **Value:** 87.26
- **Comment:** 
- **Group ID:** OG004
- **Lower Limit:** 
- **Spread:** 
- **Upper Limit:** 
- **Value:** 22.88
**Title:** 
#### Outcome Measure 10
**Class:**
##### Category
**Measurements:**
- **Comment:** 
- **Group ID:** OG000
- **Lower Limit:** 
- **Spread:** 
- **Upper Limit:** 
- **Value:** 39.39
- **Comment:** 
- **Group ID:** OG001
- **Lower Limit:** 
- **Spread:** 
- **Upper Limit:** 
- **Value:** 56.61
- **Comment:** 
- **Group ID:** OG002
- **Lower Limit:** 
- **Spread:** 
- **Upper Limit:** 
- **Value:** 71.30
- **Comment:** 
- **Group ID:** OG003
- **Lower Limit:** 
- **Spread:** 
- **Upper Limit:** 
- **Value:** 69.86
- **Comment:** 
- **Group ID:** OG004
- **Lower Limit:** 
- **Spread:** 
- **Upper Limit:** 
- **Value:** 2.25
**Title:** 
#### Outcome Measure 11
**Class:**
##### Category
**Measurements:**
- **Comment:** 
- **Group ID:** OG000
- **Lower Limit:** 
- **Spread:** 
- **Upper Limit:** 
- **Value:** 72.00
- **Comment:** 
- **Group ID:** OG001
- **Lower Limit:** 
- **Spread:** 
- **Upper Limit:** 
- **Value:** 89.47
- **Comment:** 
- **Group ID:** OG002
- **Lower Limit:** 
- **Spread:** 
- **Upper Limit:** 
- **Value:** 92.05
- **Comment:** 
- **Group ID:** OG003
- **Lower Limit:** 
- **Spread:** 
- **Upper Limit:** 
- **Value:** 90.44
- **Comment:** 
- **Group ID:** OG004
- **Lower Limit:** 
- **Spread:** 
- **Upper Limit:** 
- **Value:** 24.02
**Title:** 
#### Outcome Measure 12
**Class:**
##### Category
**Measurements:**
- **Comment:** 
- **Group ID:** OG000
- **Lower Limit:** 
- **Spread:** 
- **Upper Limit:** 
- **Value:** 46.50
- **Comment:** 
- **Group ID:** OG001
- **Lower Limit:** 
- **Spread:** 
- **Upper Limit:** 
- **Value:** 61.88
- **Comment:** 
- **Group ID:** OG002
- **Lower Limit:** 
- **Spread:** 
- **Upper Limit:** 
- **Value:** 74.75
- **Comment:** 
- **Group ID:** OG003
- **Lower Limit:** 
- **Spread:** 
- **Upper Limit:** 
- **Value:** 69.07
- **Comment:** 
- **Group ID:** OG004
- **Lower Limit:** 
- **Spread:** 
- **Upper Limit:** 
- **Value:** 8.85
**Title:** 
## Results Section
### Outcome Measures Module
#### Outcome Measure 1
**Description:** Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.
**Dispersion Type:** Standard Error
**Parameter Type:** LEAST_SQUARES_MEAN
**Population Description:** All randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline body weight value.
**Reporting Status:** POSTED
**Time Frame:** Baseline, Week 26
**Title:** Percent Change From Baseline in Body Weight in LY3502970 and Placebo
**Type:** PRIMARY
**Unit of Measure:** Percent change
##### Group
**Description:** Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks.
**ID:** OG000
**Title:** 12 mg LY3502970
##### Group
**Description:** Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks.
**ID:** OG001
**Title:** 24 mg LY3502970
##### Group
**Description:** Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-1 and dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-2 administered orally once daily until 36 weeks.
**ID:** OG002
**Title:** 36 mg LY3502970
##### Group
**Description:** Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-1 and dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-2 administered orally once daily until 36 weeks.
**ID:** OG003
**Title:** 45 mg LY3502970
##### Group
**Description:** Participants received placebo administered orally once daily until 36 weeks.
**ID:** OG004
**Title:** Placebo
#### Outcome Measure 2
**Description:** LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.
**Dispersion Type:** Standard Error
**Parameter Type:** LEAST_SQUARES_MEAN
**Population Description:** All randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline body weight value.
**Reporting Status:** POSTED
**Time Frame:** Baseline, Week 36
**Title:** Percent Change From Baseline in Body Weight in LY3502970 and Placebo
**Type:** SECONDARY
**Unit of Measure:** Percent change
##### Group
**Description:** Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks.
**ID:** OG000
**Title:** 12 mg LY3502970
##### Group
**Description:** Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks.
**ID:** OG001
**Title:** 24 mg LY3502970
##### Group
**Description:** Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-1 and dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-2 administered orally once daily until 36 weeks.
**ID:** OG002
**Title:** 36 mg LY3502970
##### Group
**Description:** Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-1 and dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-2 administered orally once daily until 36 weeks.
**ID:** OG003
**Title:** 45 mg LY3502970
##### Group
**Description:** Participants received placebo administered orally once daily until 36 weeks.
**ID:** OG004
**Title:** Placebo
#### Outcome Measure 3
**Description:** LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.
**Dispersion Type:** Standard Error
**Parameter Type:** LEAST_SQUARES_MEAN
**Population Description:** All randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline body weight value.
**Reporting Status:** POSTED
**Time Frame:** Baseline, Week 26
**Title:** Change From Baseline in Body Weight in LY3502970 and Placebo
**Type:** SECONDARY
**Unit of Measure:** kg
##### Group
**Description:** Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks.
**ID:** OG000
**Title:** 12 mg LY3502970
##### Group
**Description:** Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks.
**ID:** OG001
**Title:** 24 mg LY3502970
##### Group
**Description:** Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-1 and dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-2 administered orally once daily until 36 weeks.
**ID:** OG002
**Title:** 36 mg LY3502970
##### Group
**Description:** Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-1 and dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-2 administered orally once daily until 36 weeks.
**ID:** OG003
**Title:** 45 mg LY3502970
##### Group
**Description:** Participants received placebo administered orally once daily until 36 weeks.
**ID:** OG004
**Title:** Placebo
#### Outcome Measure 4
**Description:** LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.
**Dispersion Type:** Standard Error
**Parameter Type:** LEAST_SQUARES_MEAN
**Population Description:** All randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline body weight value.
**Reporting Status:** POSTED
**Time Frame:** Baseline, Week 36
**Title:** Change From Baseline in Body Weight in LY3502970 and Placebo
**Type:** SECONDARY
**Unit of Measure:** kg
##### Group
**Description:** Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks.
**ID:** OG000
**Title:** 12 mg LY3502970
##### Group
**Description:** Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks.
**ID:** OG001
**Title:** 24 mg LY3502970
##### Group
**Description:** Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-1 and dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-2 administered orally once daily until 36 weeks.
**ID:** OG002
**Title:** 36 mg LY3502970
##### Group
**Description:** Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-1 and dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-2 administered orally once daily until 36 weeks.
**ID:** OG003
**Title:** 45 mg LY3502970
##### Group
**Description:** Participants received placebo administered orally once daily until 36 weeks.
**ID:** OG004
**Title:** Placebo
#### Outcome Measure 5
**Description:** LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.
**Dispersion Type:** Standard Error
**Parameter Type:** LEAST_SQUARES_MEAN
**Population Description:** All randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline body waist circumference value.
**Reporting Status:** POSTED
**Time Frame:** Baseline, Week 26
**Title:** Change From Baseline in Waist Circumference in LY3502970 and Placebo
**Type:** SECONDARY
**Unit of Measure:** centimeter (cm)
##### Group
**Description:** Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks.
**ID:** OG000
**Title:** 12 mg LY3502970
##### Group
**Description:** Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks.
**ID:** OG001
**Title:** 24 mg LY3502970
##### Group
**Description:** Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-1 and dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-2 administered orally once daily until 36 weeks.
**ID:** OG002
**Title:** 36 mg LY3502970
##### Group
**Description:** Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-1 and dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-2 administered orally once daily until 36 weeks.
**ID:** OG003
**Title:** 45 mg LY3502970
##### Group
**Description:** Participants received placebo administered orally once daily until 36 weeks.
**ID:** OG004
**Title:** Placebo
#### Outcome Measure 6
**Description:** LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.
**Dispersion Type:** Standard Error
**Parameter Type:** LEAST_SQUARES_MEAN
**Population Description:** All randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline body waist circumference value.
**Reporting Status:** POSTED
**Time Frame:** Baseline, Week 36
**Title:** Change From Baseline in Waist Circumference in LY3502970 and Placebo
**Type:** SECONDARY
**Unit of Measure:** cm
##### Group
**Description:** Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks.
**ID:** OG000
**Title:** 12 mg LY3502970
##### Group
**Description:** Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks.
**ID:** OG001
**Title:** 24 mg LY3502970
##### Group
**Description:** Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-1 and dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-2 administered orally once daily until 36 weeks.
**ID:** OG002
**Title:** 36 mg LY3502970
##### Group
**Description:** Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-1 and dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-2 administered orally once daily until 36 weeks.
**ID:** OG003
**Title:** 45 mg LY3502970
##### Group
**Description:** Participants received placebo administered orally once daily until 36 weeks.
**ID:** OG004
**Title:** Placebo
#### Outcome Measure 7
**Description:** LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.
**Dispersion Type:** Standard Error
**Parameter Type:** LEAST_SQUARES_MEAN
**Population Description:** All randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline BMI value.
**Reporting Status:** POSTED
**Time Frame:** Baseline, Week 26
**Title:** Change From Baseline in BMI in LY3502970 and Placebo
**Type:** SECONDARY
**Unit of Measure:** kilograms per meter square (kg/m^2)
##### Group
**Description:** Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks.
**ID:** OG000
**Title:** 12 mg LY3502970
##### Group
**Description:** Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks.
**ID:** OG001
**Title:** 24 mg LY3502970
##### Group
**Description:** Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-1 and dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-2 administered orally once daily until 36 weeks.
**ID:** OG002
**Title:** 36 mg LY3502970
##### Group
**Description:** Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-1 and dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-2 administered orally once daily until 36 weeks.
**ID:** OG003
**Title:** 45 mg LY3502970
##### Group
**Description:** Participants received placebo administered orally once daily until 36 weeks.
**ID:** OG004
**Title:** Placebo
#### Outcome Measure 8
**Description:** LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.
**Dispersion Type:** Standard Error
**Parameter Type:** LEAST_SQUARES_MEAN
**Population Description:** All randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline BMI value.
**Reporting Status:** POSTED
**Time Frame:** Baseline, Week 36
**Title:** Change From Baseline in BMI in LY3502970 and Placebo
**Type:** SECONDARY
**Unit of Measure:** kg/m^2
##### Group
**Description:** Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks.
**ID:** OG000
**Title:** 12 mg LY3502970
##### Group
**Description:** Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks.
**ID:** OG001
**Title:** 24 mg LY3502970
##### Group
**Description:** Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-1 and dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-2 administered orally once daily until 36 weeks.
**ID:** OG002
**Title:** 36 mg LY3502970
##### Group
**Description:** Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-1 and dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-2 administered orally once daily until 36 weeks.
**ID:** OG003
**Title:** 45 mg LY3502970
##### Group
**Description:** Participants received placebo administered orally once daily until 36 weeks.
**ID:** OG004
**Title:** Placebo
#### Outcome Measure 9
**Description:** Percentage of participants with \>=5% body weight loss was reported.
**Parameter Type:** NUMBER
**Population Description:** All randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline value for ≥5% body weight reduction.
**Reporting Status:** POSTED
**Time Frame:** Week 26
**Title:** Percentage of Participants With >=5% Body Weight Loss
**Type:** SECONDARY
**Unit of Measure:** percentage of participants
##### Group
**Description:** Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks.
**ID:** OG000
**Title:** 12 mg LY3502970
##### Group
**Description:** Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks.
**ID:** OG001
**Title:** 24 mg LY3502970
##### Group
**Description:** Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-1 and dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-2 administered orally once daily until 36 weeks.
**ID:** OG002
**Title:** 36 mg LY3502970
##### Group
**Description:** Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-1 and dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-2 administered orally once daily until 36 weeks.
**ID:** OG003
**Title:** 45 mg LY3502970
##### Group
**Description:** Participants received placebo administered orally once daily until 36 weeks.
**ID:** OG004
**Title:** Placebo
#### Outcome Measure 10
**Description:** Percentage of participants with \>=10% body weight loss was reported.
**Parameter Type:** NUMBER
**Population Description:** All randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline value for ≥10% body weight reduction.
**Reporting Status:** POSTED
**Time Frame:** Week 26
**Title:** Percentage of Participants With >=10% Body Weight Loss
**Type:** SECONDARY
**Unit of Measure:** percentage of participants
##### Group
**Description:** Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks.
**ID:** OG000
**Title:** 12 mg LY3502970
##### Group
**Description:** Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks.
**ID:** OG001
**Title:** 24 mg LY3502970
##### Group
**Description:** Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-1 and dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-2 administered orally once daily until 36 weeks.
**ID:** OG002
**Title:** 36 mg LY3502970
##### Group
**Description:** Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-1 and dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-2 administered orally once daily until 36 weeks.
**ID:** OG003
**Title:** 45 mg LY3502970
##### Group
**Description:** Participants received placebo administered orally once daily until 36 weeks.
**ID:** OG004
**Title:** Placebo
#### Outcome Measure 11
**Description:** Percentage of participants with \>=5% body weight loss was reported.
**Parameter Type:** NUMBER
**Population Description:** All randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline value for ≥5% body weight reduction.
**Reporting Status:** POSTED
**Time Frame:** Week 36
**Title:** Percentage of Participants With >=5% Body Weight Loss
**Type:** SECONDARY
**Unit of Measure:** percentage of participants
##### Group
**Description:** Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks.
**ID:** OG000
**Title:** 12 mg LY3502970
##### Group
**Description:** Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks.
**ID:** OG001
**Title:** 24 mg LY3502970
##### Group
**Description:** Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-1 and dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-2 administered orally once daily until 36 weeks.
**ID:** OG002
**Title:** 36 mg LY3502970
##### Group
**Description:** Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-1 and dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-2 administered orally once daily until 36 weeks.
**ID:** OG003
**Title:** 45 mg LY3502970
##### Group
**Description:** Participants received placebo administered orally once daily until 36 weeks.
**ID:** OG004
**Title:** Placebo
#### Outcome Measure 12
**Description:** Percentage of participants with \>=10% body weight loss was reported.
**Parameter Type:** NUMBER
**Population Description:** All randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline value for ≥10% body weight reduction.
**Reporting Status:** POSTED
**Time Frame:** Week 36
**Title:** Percentage of Participants With >=10% Body Weight Loss
**Type:** SECONDARY
**Unit of Measure:** percentage of participants
##### Group
**Description:** Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks.
**ID:** OG000
**Title:** 12 mg LY3502970
##### Group
**Description:** Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks.
**ID:** OG001
**Title:** 24 mg LY3502970
##### Group
**Description:** Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-1 and dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-2 administered orally once daily until 36 weeks.
**ID:** OG002
**Title:** 36 mg LY3502970
##### Group
**Description:** Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-1 and dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-2 administered orally once daily until 36 weeks.
**ID:** OG003
**Title:** 45 mg LY3502970
##### Group
**Description:** Participants received placebo administered orally once daily until 36 weeks.
**ID:** OG004
**Title:** Placebo
### Participant Flow Module
#### Group
**Description:** Participants received maintenance dose 12 mg with dose escalation starting from 3 mg, 6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks.
**ID:** FG000
**Title:** 12 mg LY3502970
#### Group
**Description:** Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks.
**ID:** FG001
**Title:** 24 mg LY3502970
#### Group
**Description:** Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.
**ID:** FG002
**Title:** 36 mg -1 LY3502970
#### Group
**Description:** Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.
**ID:** FG003
**Title:** 36 mg -2 LY3502970
#### Group
**Description:** Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.
**ID:** FG004
**Title:** 45 mg -1 LY3502970
#### Group
**Description:** Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.
**ID:** FG005
**Title:** 45 mg -2 LY3502970
#### Group
**Description:** Participants received placebo administered orally once daily until 36 weeks.
**ID:** FG006
**Title:** Placebo
#### Period
**Title:** Overall Study
##### Withdraw
**Type:** Withdrawal by Subject
###### Reason
**Group ID:** FG000
**Number of Subjects:** 3
###### Reason
**Group ID:** FG001
**Number of Subjects:** 5
###### Reason
**Group ID:** FG002
**Number of Subjects:** 2
###### Reason
**Group ID:** FG003
**Number of Subjects:** 1
###### Reason
**Group ID:** FG004
**Number of Subjects:** 4
###### Reason
**Group ID:** FG005
**Number of Subjects:** 0
###### Reason
**Group ID:** FG006
**Number of Subjects:** 4
##### Withdraw
**Type:** Lost to Follow-up
###### Reason
**Group ID:** FG000
**Number of Subjects:** 1
###### Reason
**Group ID:** FG001
**Number of Subjects:** 0
###### Reason
**Group ID:** FG002
**Number of Subjects:** 0
###### Reason
**Group ID:** FG003
**Number of Subjects:** 0
###### Reason
**Group ID:** FG004
**Number of Subjects:** 1
###### Reason
**Group ID:** FG005
**Number of Subjects:** 0
###### Reason
**Group ID:** FG006
**Number of Subjects:** 1
##### Withdraw
**Type:** Subject Unable to Visit Due to Working Out of Town
###### Reason
**Group ID:** FG000
**Number of Subjects:** 0
###### Reason
**Group ID:** FG001
**Number of Subjects:** 0
###### Reason
**Group ID:** FG002
**Number of Subjects:** 0
###### Reason
**Group ID:** FG003
**Number of Subjects:** 0
###### Reason
**Group ID:** FG004
**Number of Subjects:** 0
###### Reason
**Group ID:** FG005
**Number of Subjects:** 0
###### Reason
**Group ID:** FG006
**Number of Subjects:** 1
##### Withdraw
**Type:** Adverse Event
###### Reason
**Group ID:** FG000
**Number of Subjects:** 2
###### Reason
**Group ID:** FG001
**Number of Subjects:** 1
###### Reason
**Group ID:** FG002
**Number of Subjects:** 0
###### Reason
**Group ID:** FG003
**Number of Subjects:** 4
###### Reason
**Group ID:** FG004
**Number of Subjects:** 1
###### Reason
**Group ID:** FG005
**Number of Subjects:** 2
###### Reason
**Group ID:** FG006
**Number of Subjects:** 0
##### Withdraw
**Type:** Inadvertent Enrollment
###### Reason
**Group ID:** FG000
**Number of Subjects:** 0
###### Reason
**Group ID:** FG001
**Number of Subjects:** 0
###### Reason
**Group ID:** FG002
**Number of Subjects:** 0
###### Reason
**Group ID:** FG003
**Number of Subjects:** 0
###### Reason
**Group ID:** FG004
**Number of Subjects:** 0
###### Reason
**Group ID:** FG005
**Number of Subjects:** 0
###### Reason
**Group ID:** FG006
**Number of Subjects:** 1
##### Withdraw
**Type:** Subject Could not Tolerate Investigational Product (IP) and was Taken Off
###### Reason
**Group ID:** FG000
**Number of Subjects:** 0
###### Reason
**Group ID:** FG001
**Number of Subjects:** 1
###### Reason
**Group ID:** FG002
**Number of Subjects:** 0
###### Reason
**Group ID:** FG003
**Number of Subjects:** 0
###### Reason
**Group ID:** FG004
**Number of Subjects:** 0
###### Reason
**Group ID:** FG005
**Number of Subjects:** 0
###### Reason
**Group ID:** FG006
**Number of Subjects:** 0
##### Withdraw
**Type:** Sponsor Decision
###### Reason
**Group ID:** FG000
**Number of Subjects:** 0
###### Reason
**Group ID:** FG001
**Number of Subjects:** 0
###### Reason
**Group ID:** FG002
**Number of Subjects:** 0
###### Reason
**Group ID:** FG003
**Number of Subjects:** 0
###### Reason
**Group ID:** FG004
**Number of Subjects:** 1
###### Reason
**Group ID:** FG005
**Number of Subjects:** 0
###### Reason
**Group ID:** FG006
**Number of Subjects:** 0
##### Withdraw
**Type:** Patient was Initially Long Term Follow-up But Contacted and came to Site After Follow-up
###### Reason
**Group ID:** FG000
**Number of Subjects:** 0
###### Reason
**Group ID:** FG001
**Number of Subjects:** 0
###### Reason
**Group ID:** FG002
**Number of Subjects:** 0
###### Reason
**Group ID:** FG003
**Number of Subjects:** 0
###### Reason
**Group ID:** FG004
**Number of Subjects:** 1
###### Reason
**Group ID:** FG005
**Number of Subjects:** 0
###### Reason
**Group ID:** FG006
**Number of Subjects:** 0
##### Milestone
**Type:** STARTED
###### Achievement
**Group ID:** FG000
**Number of Subjects:** 50
###### Achievement
**Group ID:** FG001
**Number of Subjects:** 53
###### Achievement
**Group ID:** FG002
**Number of Subjects:** 29
###### Achievement
**Group ID:** FG003
**Number of Subjects:** 29
###### Achievement
**Group ID:** FG004
**Number of Subjects:** 31
###### Achievement
**Group ID:** FG005
**Number of Subjects:** 30
###### Achievement
**Group ID:** FG006
**Number of Subjects:** 50
##### Milestone
**Type:** COMPLETED
###### Achievement
**Group ID:** FG000
**Number of Subjects:** 44
###### Achievement
**Group ID:** FG001
**Number of Subjects:** 46
###### Achievement
**Group ID:** FG002
**Number of Subjects:** 27
###### Achievement
**Group ID:** FG003
**Number of Subjects:** 24
###### Achievement
**Group ID:** FG004
**Number of Subjects:** 23
###### Achievement
**Group ID:** FG005
**Number of Subjects:** 28
###### Achievement
**Group ID:** FG006
**Number of Subjects:** 43
##### Milestone
**Type:** NOT COMPLETED
###### Achievement
**Group ID:** FG000
**Number of Subjects:** 6
###### Achievement
**Group ID:** FG001
**Number of Subjects:** 7
###### Achievement
**Group ID:** FG002
**Number of Subjects:** 2
###### Achievement
**Group ID:** FG003
**Number of Subjects:** 5
###### Achievement
**Group ID:** FG004
**Number of Subjects:** 8
###### Achievement
**Group ID:** FG005
**Number of Subjects:** 2
###### Achievement
**Group ID:** FG006
**Number of Subjects:** 7
**Pre-Assignment Details:** For maintenance doses of LY3502970: 12, 24, 36, and 45 milligram (mg), the initial dose will be 2 or 3 mg followed by additional escalation steps as appropriate. The dose-escalation varied by dose group where the target maintenance dose was achieved between Weeks 5 and 16.
**Has Results:** True